Difference between revisions of "Malignant solid neoplasm, BRAF-mutated"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "https://ascopubs.org/doi/full/10.1200" to "https://doi.org/10.1200") |
m |
||
| Line 32: | Line 32: | ||
*No prior treatment with [[:Category:BRAF inhibitors|BRAF]] and/or [[:Category:MEK inhibitors|MEK]] inhibitor(s) | *No prior treatment with [[:Category:BRAF inhibitors|BRAF]] and/or [[:Category:MEK inhibitors|MEK]] inhibitor(s) | ||
| − | ==== | + | ====Targeted therapy==== |
*[[Dabrafenib (Tafinlar)]] 150 mg PO twice per day | *[[Dabrafenib (Tafinlar)]] 150 mg PO twice per day | ||
| Line 44: | Line 44: | ||
==Vemurafenib monotherapy {{#subobject:e0d17a|Regimen=1}}== | ==Vemurafenib monotherapy {{#subobject:e0d17a|Regimen=1}}== | ||
| + | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
| + | |- | ||
| + | |[[#top|back to top]] | ||
| + | |} | ||
===Regimen {{#subobject:392a4b|Variant=1}}=== | ===Regimen {{#subobject:392a4b|Variant=1}}=== | ||
{| class="wikitable" style="width: 50%; text-align:center;" | {| class="wikitable" style="width: 50%; text-align:center;" | ||
| Line 71: | Line 75: | ||
*''VE-BASKET'': no prior treatment with [[:Category:BRAF inhibitors|BRAF]] and/or [[:Category:MEK inhibitors|MEK]] inhibitor(s) | *''VE-BASKET'': no prior treatment with [[:Category:BRAF inhibitors|BRAF]] and/or [[:Category:MEK inhibitors|MEK]] inhibitor(s) | ||
| − | ==== | + | ====Targeted therapy==== |
| − | *[ | + | *[[Vemurafenib (Zelboraf)]] 960 mg PO twice per day |
'''Continued indefinitely''' | '''Continued indefinitely''' | ||
Revision as of 15:04, 24 August 2020
2 regimens on this page
2 variants on this page
|
Note: this is a new type of page for HemOnc.org, as most other regimen pages are tissue-specific. We will collect published information from basket trials on these pages, as well as regimens that are FDA approved.
All lines of therapy
Dabrafenib & Trametinib
| back to top |
Regimen
| Study | Evidence |
|---|---|
| Subbiah et al. 2017 (BRF117019) | Phase II |
Note: only partial results have been published to date.
Biomarker eligibility criteria
- Gene: BRAF V600E
- Alteration: substitution
- Acceptable methods of measurement: archival or fresh tumor tissue
Preceding treatment
Targeted therapy
- Dabrafenib (Tafinlar) 150 mg PO twice per day
- Trametinib (Mekinist) 2 mg PO once per day
Continued indefinitely
References
- BRF117019: Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam B. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018 Jan 1;36(1):7-13. Epub 2017 Oct 26. link to original article contains verified protocol link to PMC article PubMed
Vemurafenib monotherapy
| back to top |
Regimen
| Study | Evidence |
|---|---|
| Hyman et al. 2015 (VE-BASKET) | Phase II |
| Hainsworth et al. 2018 (MyPathway) | Phase IIa |
Biomarker eligibility criteria
- VE-BASKET
- Gene: BRAF V600
- Alteration: substitution
- Acceptable methods of measurement: mutational analysis assays
- MyPathway
- Gene: BRAF V600E
- Alteration: substitution
- Acceptable methods of measurement: molecular profiling performed on tissue obtained at the most recent tumor biopsy
- Biomarker exclusions: no coexisting KRAS mutations, or other BRAF mutations
Preceding treatment
Targeted therapy
- Vemurafenib (Zelboraf) 960 mg PO twice per day
Continued indefinitely
References
- VE-BASKET: Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, Gervais R, Elez-Fernandez ME, Italiano A, Hofheinz RD, Hidalgo M, Chan E, Schuler M, Lasserre SF, Makrutzki M, Sirzen F, Veronese ML, Tabernero J, Baselga J. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015 Aug 20;373(8):726-736. link to original article contains protocol link to PMC article PubMed
- MyPathway: Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. link to original article contains verified protocol PubMed